[Optical coherence tomography angiography in vascular eye diseases]

Argento F, García Marti S, Alfie V, Navarro E, Augustovski F, Ciapponi A, Bardach A, Pichon Riviere A, Alcaraz A
Record ID 32018004430
Spanish
Original Title: Angiografía por tomografía de coherencia óptica en enfermedades vasculares del ojo
Authors' recommendations: Low-quality evidence suggests that Optical Coherence Tomography Angiography (OCTA) in vascular eye diseases (wet age-related macular degeneration and diabetic retinopathy) usually has a lower net benefit since it has a diagnostic capacity similar to that of angiography and prevents the moderate or severe adverse effects related to this invasive procedure. It is worth pointing out that performing OCTA could have a positive organizational impact on the provider institution, as long as it has the device, due to the simplicity and speed in implementing this technology. The guidelines consulted mention OCTA and consider it as an alternative in patients with diabetic retinopathy or wet age-related macular degeneration; however, the reference diagnostic method is still the fluorescein angiography in optical coherence tomography. The coverage policies consulted do not mention this technology No studies assessing the cost-effectiveness of this technology have been found for any of the indications assessed.
Details
Project Status: Completed
Year Published: 2022
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Diabetic Retinopathy
  • Wet Macular Degeneration
  • Macular Degeneration
  • Tomography, Optical Coherence
  • Diagnosis
  • Visual Acuity
  • Fluorescein Angiography
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.